Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI-generated claim that SYMPAZAN labeling warns of risks from concomitant use with opioids is directly supported by the provided FDA label text (Sections 5.1, 7.1, and patient counseling in 17), including specific risk-mitigation guidance (reserve combination, lowest effective dose/shortest duration, and close monitoring).
Category Scores
Accurate Statements
Concomitant use of benzodiazepines (including SYMPAZAN) and opioids may result in profound sedation, respiratory depression, coma, and death, and therefore concomitant prescribing should be reserved for patients with inadequate alternative options.
Label Section 5.1
If SYMPAZAN is used concomitantly with opioids, prescribe the lowest effective dosages and minimum durations and follow patients closely for signs/symptoms of respiratory depression and sedation.
Label Section 5.1
The labeling notes the concomitant use increases risk of respiratory depression with benzodiazepines and opioids and advises limiting dose/duration and monitoring for respiratory depression and sedation.
Label Section 7.1
Patients and caregivers should be informed about potentially fatal additive effects if SYMPAZAN is used with opioids and not to use such drugs concomitantly unless supervised by a healthcare provider.
Label Section 17
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated output concerns the presence and content of a major opioid concomitant-use warning; the statements are consistent with the provided label risk language and mitigation steps.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement